Immunotherapy is a cancer treatment that aids the immune system in fighting the disease. Hormone therapy is a treatment that slows or stops the growth of cancers that utilize hormones to proliferate, such as breast and prostate cancer. Anticancer medications stop cancer cells from dividing and multiplying, and they are less selective against cancer cells. As a result, these medications not only kill cancer cells but also normal cells. Chemotherapy and anticancer medications are substances that denature cancer cells by halting their growth. Anticancer medications have an effect on cancer cell division, but they also have an effect on normal cells.
The rise in the prevalence of cancer disease and the
incidence of various cancer conditions, as well as the popularity of advanced
therapies (biological and targeted pharmacological therapies) and the global
elderly population, are driving the expansion of the Oncology
Drug Pipeline Analysis Market. Furthermore, increased cancer
awareness and early cancer screening contribute to the growth of the oncology
medications industry. However, the high costs associated with new medication
development, as well as the risk of failure and side effects associated with
cancer treatment therapies, are limiting the market's expansion. Conversely,
during the projected period, the high potential of rising economies and the
greater number of prospective medications in the pipeline are expected to
provide profitable prospects.
The industry is predicted to rise due to increased government
spending in oncology research. For example, the US Food and Drug Administration
(FDA) awarded over US$ 18 million for new clinical trial research in September
2018, with 33% of it going to uncommon cancers like advanced pancreatic cancer,
head and neck squamous cell carcinoma, and acute myeloid leukaemia. To increase
their share of the Oncology Drug Pipeline Analysis Market, key players are
focusing on acquisitions and collaborations.